E Fund Management Co. Ltd. Has $373,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

E Fund Management Co. Ltd. raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 74.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,530 shares of the medical equipment provider’s stock after buying an additional 1,508 shares during the period. E Fund Management Co. Ltd.’s holdings in Zimmer Biomet were worth $373,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $473,000. Geode Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares during the period. M&T Bank Corp lifted its holdings in shares of Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after purchasing an additional 8,709 shares during the period. KLCM Advisors Inc. acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $654,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 2.4 %

ZBH opened at $107.87 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market cap of $21.47 billion, a P/E ratio of 24.24, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a fifty day moving average price of $105.55 and a two-hundred day moving average price of $107.19.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the company earned $2.20 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of recent research reports. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. JMP Securities reiterated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James cut their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Barclays cut their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Finally, Truist Financial reiterated a “hold” rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.